Erlonat Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing Local Product Insert

Full Prescribing Info

Adverse Reactions

Adverse effect occurring in 10% or more of patients receiving erlotinib monotherapy in one clinical study and with an incidence at least 3% more frequent than with placebo included rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, infection, vomiting, stomatitis, pruritus, dry skin, conjunctivitis, keratoconjunctivitis sicca, and abdominal pain.
The adverse effects occurring most frequently (incidence greater than 30%) in patients receiving erlotinib and gemcitabine for pancreatic cancer in a randomized trial included fatigue, rash, nausea, anorexia, diarrhea, abdominal pain, vomiting, decreased weight, infection, edema, pyrexia, and constipation.

View ADR Monitoring Form

Erlonat Adverse Reactions

erlotinib

Manufacturer:

Natco Pharma

Distributor:

Atlanta Medicare